AbCellera Biologics. has filed a patent for a method to produce mice with B cells expressing diverse heavy chain-only antibodies. The method involves incorporating a transgenic gene segment and modifying the endogenous gene segment to enhance antibody production. GlobalData’s report on AbCellera Biologics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights AbCellera Biologics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AbCellera Biologics, Molecular diagnosis biomarkers was a key innovation area identified from patents. AbCellera Biologics's grant share as of January 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.

Creating mice with diverse heavy chain-only antibodies for research

Source: United States Patent and Trademark Office (USPTO). Credit: AbCellera Biologics Inc

A patent application (Publication Number: US20240023526A1) describes a method for producing a mouse with B cells expressing a diverse repertoire of heavy chain-only antibodies (HCAb). This method involves incorporating a transgenic Cy gene segment upstream of the endogenous Cµ gene segment within the immunoglobulin heavy chain constant region locus. The C? gene segment includes a deletion of a nucleotide sequence encoding part of the CH1 domain, with the endogenous Cµ gene segment being inactive due to various mutations. The resulting mouse, when immunized with an antigen, activates antigen-specific B cells that differentiate into plasmacytes secreting a variety of antigen-specific HCAb.

Furthermore, the patent application details the positioning of the C? gene segment downstream of an Eµ major intron enhancer and the inclusion of human VH, D, and JH coding sequences within the immunoglobulin heavy chain locus. The method also involves providing murine embryonic stem cells, introducing vectors containing the C? gene segment, selecting transgenic cells with the incorporated sequences, and utilizing them to create a transgenic mouse. The resulting mouse, with a diverse repertoire of HCAb, can be used to produce antibodies with antigen-specific VH domains. Additionally, the patent application highlights the use of this transgenic mouse in methods for producing B cell repertoires or VH-containing molecules, showcasing the potential applications of this technology in antibody production and research.

To know more about GlobalData’s detailed insights on AbCellera Biologics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies